Recent studies have also demonstrated that neutralization of secreted FABP4 with an antibody to FABP4 could be a feasible approach for treatment of insulin resistance, type 2 diabetes mellitus, vascular injury and atherosclerosis [7–9]. The gene discussed is FABP4; the disease is diabetes mellitus.